INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept Therapeutics Incorporated – CORT

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Corcept Therapeutics and its officers or directors, following a significant stock price drop after the FDA's Complete Response Letter regarding a new drug application [1][3]. Group 1: Company Overview - Corcept Therapeutics Incorporated is a biopharmaceutical company focused on developing treatments for patients with conditions related to cortisol excess [3]. - The company’s stock price experienced a dramatic decline of $35.40 per share, or 50.42%, closing at $34.80 per share on December 31, 2025, after the FDA issued a Complete Response Letter regarding its drug relacorilant [3]. Group 2: Regulatory Developments - On December 31, 2025, the FDA issued a Complete Response Letter concerning Corcept's New Drug Application for relacorilant, indicating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness was required for a favorable benefit-risk assessment [3]. Group 3: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is currently investigating claims on behalf of investors of Corcept, suggesting potential legal ramifications for the company and its leadership [1][4].